Andrew B West

List of Publications by Year
in descending order

93 papers	11,991 citations	38742 50 h-index	43889 91 g-index
108 all docs	108 docs citations	108 times ranked	11858 citing authors

#	Article	IF	Citations
1	Pathological Î±-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain. Molecular Neurodegeneration, 2022, 17, 7.	10.8	34
2	Evaluation of ABT-888 in the amelioration of Î±-synuclein fibril-induced neurodegeneration. Brain Communications, 2022, 4, fcac042.	3.3	1
3	Elevated Urinary Rab10 Phosphorylation in Idiopathic Parkinson Disease. Movement Disorders, 2022, 37, 1454-1464.	3.9	13
4	Evaluation of Current Methods to Detect Cellular Leucine-Rich Repeat Kinase 2 (LRRK2) Kinase Activity. Journal of Parkinson's Disease, 2022, 12, 1423-1447.	2.8	8
5	Genetic and Environmental Factors in <scp>P</scp>arkinson's Disease Converge on Immune Function and Inflammation. Movement Disorders, 2021, 36, 25-36.	3.9	69
6	Heterogeneity in Î±-synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. Acta Neuropathologica, 2021, 141, 547-564.	7.7	23
7	Identification of <i>LRRK2</i> missense variants in the accelerating medicines partnership Parkinsonâ€™s disease cohort. Human Molecular Genetics, 2021, 30, 454-466.	2.9	20
8	Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease. Npj Parkinson's Disease, 2021, 7, 36.	5.3	26
9	Association of Dual <i>LRRK2 </i>G2019S and <i>GBA</i> Variations With Parkinson Disease Progression. JAMA Network Open, 2021, 4, e215845.	5.9	38
10	Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain. Brain Research, 2021, 1759, 147372.	2.2	8
11	Inhibition of LRRK2 kinase activity promotes anterograde axonal transport and presynaptic targeting of Î±-synuclein. Acta Neuropathologica Communications, 2021, 9, 180.	5.2	16
12	Pharmacodynamic Biomarkers for Emerging LRRK2 Therapeutics. Frontiers in Neuroscience, 2020, 14, 807.	2.8	17
13	Exosome markers of LRRK2 kinase inhibition. Npj Parkinson's Disease, 2020, 6, 32.	5.3	15
14	LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes. EMBO Journal, 2020, 39, e104862.	7.8	58
15	Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17296-17307.	7.1	47
16	Parkinson disease and the immune system â€” associations, mechanisms and therapeutics. Nature Reviews Neurology, 2020, 16, 303-318.	10.1	254
17	Proteomic analysis of urinary extracellular vesicles reveal biomarkers for neurologic disease. EBioMedicine, 2019, 45, 351-361.	6.1	99
18	Caught in the act: LRRK2 in exosomes. Biochemical Society Transactions, 2019, 47, 663-670.	3.4	12

#	Article	IF	Citations
19	The unlikely partnership between <scp>LRRK</scp>2 and Î±â€synuclein in Parkinson's disease. European Journal of Neuroscience, 2019, 49, 339-363.	2.6	35
20	LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. Human Molecular Genetics, 2018, 27, 385-395.	2.9	218
21	The G2019S mutation in LRRK2 imparts resiliency to kinase inhibition. Experimental Neurology, 2018, 309, 1-13.	4.1	40
22	Finding useful biomarkers for Parkinsonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	125
23	Sensitivity and specificity of phosphoâ€Ser129 Î±â€synuclein monoclonal antibodies. Journal of Comparative Neurology, 2018, 526, 1978-1990.	1.6	55
24	LRRK2 levels in immune cells are increased in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2017, 3, 11.	5.3	177
25	Î±-Synuclein fibril-induced inclusion spread in rats and mice correlates with dopaminergic Neurodegeneration. Neurobiology of Disease, 2017, 105, 84-98.	4.4	129
26	The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 274-280.	2.3	2
27	Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease. Experimental Neurology, 2017, 298, 236-245.	4.1	123
28	LRRK2 Antisense Oligonucleotides Ameliorate Î±-Synuclein Inclusion Formation in a Parkinsonâ€™s Disease Mouse Model. Molecular Therapy - Nucleic Acids, 2017, 8, 508-519.	5.1	167
29	Parkinson's disease biomarkers: perspective from the NINDS Parkinson's Disease Biomarkers Program. Biomarkers in Medicine, 2017, 11, 451-473.	1.4	49
30	Exaggerated CpH methylation in the autism-affected brain. Molecular Autism, 2017, 8, 6.	4.9	31
31	Breathing new life into an old target: pulmonary disease drugs for Parkinsonâ€™s disease therapy. Genome Medicine, 2017, 9, 88.	8.2	6
32	Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers. Acta Neuropathologica Communications, 2017, 5, 86.	5.2	68
33	Î±-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration. Acta Neuropathologica Communications, 2017, 5, 85.	5.2	129
34	Identification of bonaâ€fide LRRK2 kinase substrates. Movement Disorders, 2016, 31, 1140-1141.	3.9	15
35	The NINDS Parkinson's disease biomarkers program. Movement Disorders, 2016, 31, 915-923.	3.9	83
36	Ser(P)â€1292 LRRK2 in urinary exosomes is elevated in idiopathic Parkinson's disease. Movement Disorders, 2016, 31, 1543-1550.	3.9	144

#	Article	IF	Citations
37	G2019S-LRRK2 Expression Augments Â-Synuclein Sequestration into Inclusions in Neurons. Journal of Neuroscience, 2016, 36, 7415-7427.	3.6	156
38	Urinary LRRK2 phosphorylation predicts parkinsonian phenotypes in G2019S <i>LRRK2</i> carriers. Neurology, 2016, 86, 994-999.	1.1	114
39	14-3-3 Proteins regulate mutant LRRK2 kinase activity and neurite shortening. Human Molecular Genetics, 2016, 25, 109-122.	2.9	64
40	LRRK2 autophosphorylation enhances its GTPase activity. FASEB Journal, 2016, 30, 336-347.	0.5	48
41	Ten <scp>Y</scp>ears and <scp>C</scp>ounting: <scp>M</scp>oving <scp>L</scp>eucineâ€«scp>R</scp>ich <scp>Repeat</scp><scp>K</scp>inase 2 <scp>I</scp>nhibitors to the <scp>C</scp>linic. Movement Disorders, 2015, 30, 180-189.	3.9	60
42	The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Human Molecular Genetics, 2015, 24, 4250-4267.	2.9	58
43	Leucine-rich repeat kinase 2 deficiency is protective in rhabdomyolysis-induced kidney injury. Human Molecular Genetics, 2015, 24, 4078-4093.	2.9	39
44	Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates Î±-Synuclein Gene-induced Neurodegeneration. Journal of Biological Chemistry, 2015, 290, 19433-19444.	3.4	171
45	PGC-1Î± Provides a Transcriptional Framework for Synchronous Neurotransmitter Release from Parvalbumin-Positive Interneurons. Journal of Neuroscience, 2014, 34, 14375-14387.	3.6	64
46	Unique Functional and Structural Properties of the LRRK2 Protein ATP-binding Pocket. Journal of Biological Chemistry, 2014, 289, 32937-32951.	3.4	26
47	Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. Journal of Comparative Neurology, 2014, 522, Spc1-Spc1.	1.6	2
48	Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nature Communications, 2014, 5, 5748.	12.8	478
49	Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. Journal of Comparative Neurology, 2014, 522, 2465-2480.	1.6	110
50	Formation of Î±-synuclein Lewy neuriteâ€"like aggregates in axons impedes the transport of distinct endosomes. Molecular Biology of the Cell, 2014, 25, 4010-4023.	2.1	202
51	Abrogation of Î±-synucleinâ€"mediated dopaminergic neurodegeneration in LRRK2-deficient rats. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 9289-9294.	7.1	187
52	Hyperactivity and cortical disinhibition in mice with restricted expression of mutant huntingtin to parvalbumin-positive cells. Neurobiology of Disease, 2014, 62, 160-171.	4.4	15
53	Basal Ganglia Disorders. , 2013, , 1-39.		0
54	LRRK2 secretion in exosomes is regulated by 14-3-3. Human Molecular Genetics, 2013, 22, 4988-5000.	2.9	142

#	Article	IF	Citations
55	RNA-Seq optimization with eQTL gold standards. BMC Genomics, 2013, 14, 892.	2.8	24
56	Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochemical Journal, 2013, 453, 101-113.	3.7	84
57	Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biology, 2013, 14, R102.	9.6	291
58	Defining the Contribution of CNTNAP2 to Autism Susceptibility. PLoS ONE, 2013, 8, e77906.	2.5	33
59	GTPase Activity and Neuronal Toxicity of Parkinson's Diseaseâ€"Associated LRRK2 Is Regulated by ArfGAP1. PLoS Genetics, 2012, 8, e1002526.	3.5	122
60	LRRK2 Inhibition Attenuates Microglial Inflammatory Responses. Journal of Neuroscience, 2012, 32, 1602-1611.	3.6	386
61	Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations. PLoS ONE, 2012, 7, e47784.	2.5	39
62	Autophosphorylation in the Leucine-Rich Repeat Kinase 2 (LRRK2) GTPase Domain Modifies Kinase and GTP-Binding Activities. Journal of Molecular Biology, 2011, 412, 94-110.	4.2	117
63	Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death. Nature Medicine, 2011, 17, 692-699.	30.7	190
64	Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1439-1444.	7.1	87
65	Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease. Movement Disorders, 2010, 25, 2156-2163.	3.9	108
66	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	30.7	342
67	Identification and Characterization of a Leucine-Rich Repeat Kinase 2 (LRRK2) Consensus Phosphorylation Motif. PLoS ONE, 2010, 5, e13672.	2.5	66
68	The Therapeutic Potential of LRRK2 and Î±-Synuclein in Parkinson's Disease. Antioxidants and Redox Signaling, 2009, 11, 2167-2187.	5.4	9
69	Dependence of Leucine-rich Repeat Kinase 2 (LRRK2) Kinase Activity on Dimerization. Journal of Biological Chemistry, 2009, 284, 36346-36356.	3.4	164
70	A genome-wide linkage and association scan reveals novel loci for autism. Nature, 2009, 461, 802-808.	27.8	570
71	Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nature Cell Biology, 2009, 11, 1370-1375.	10.3	173
72	LRRK2 in Parkinsonâ€™s disease: function in cells and neurodegeneration. FEBS Journal, 2009, 276, 6436-6444.	4.7	29

#	Article	IF	Citations
73	Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 625-633.	3.8	91
74	Revelations and revolutions in the understanding of Parkinsonâ€™s disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 585-586.	3.8	3
75	Parkin mediates the degradationâ€independent ubiquitination of Hsp70. Journal of Neurochemistry, 2008, 105, 1806-1819.	3.9	101
76	Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Human Molecular Genetics, 2007, 16, 223-232.	2.9	535
77	Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neuroscience, 2007, 8, 102.	1.9	135
78	Localization of Parkinsonâ€™s disease-associated LRRK2 in normal and pathological human brain. Brain Research, 2007, 1155, 208-219.	2.2	139
79	Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology, 2006, 60, 557-569.	5.3	479
80	Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18676-18681.	7.1	390
81	MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE. Annual Review of Neuroscience, 2005, 28, 57-87.	10.7	1,111
82	Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16842-16847.	7.1	1,084
83	To die or grow: Parkinson's disease and cancer. Trends in Neurosciences, 2005, 28, 348-352.	8.6	110
84	N-myc Regulates Parkin Expression. Journal of Biological Chemistry, 2004, 279, 28896-28902.	3.4	46
85	Genetics of parkin-linked disease. Human Genetics, 2004, 114, 327-336.	3.8	98
86	Identification of a Novel Gene Linked to Parkin via a Bi-directional Promoter. Journal of Molecular Biology, 2003, 326, 11-19.	4.2	111
87	Parkin is not regulated by the unfolded protein response in human neuroblastoma cells. Neuroscience Letters, 2003, 341, 139-142.	2.1	17
88	Identification of a Novel Gene Linked to Parkin via a Bidirectional Promoter. Annals of the New York Academy of Sciences, 2003, 991, 311-314.	3.8	0
89	Functional association of the parkin gene promoter with idiopathic Parkinson's disease. Human Molecular Genetics, 2002, 11, 2787-2792.	2.9	95
90	Complex relationship between Parkin mutations and Parkinson disease. American Journal of Medical Genetics Part A, 2002, 114, 584-591.	2.4	193

#	Article	IF	Citations
91	Clinical,18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism andparkin gene mutations. Movement Disorders, 2002, 17, 670-675.	3.9	44
92	Identification and characterization of the human parkin gene promoter. Journal of Neurochemistry, 2001, 78, 1146-1152.	3.9	31
93	Refinement of the PARK3 locus on chromosome 2p13 and the analysis of 14 candidate genes. European Journal of Human Genetics, 2001, 9, 659-666.	2.8	46